Hershey beats quarterly sales estimates

Regeneron has exceeded its quarterly estimates, driven primarily by the strong performance of its eczema drug, which led to an increase in share prices. Simultaneously, Hershey has also outperformed market expectations for its quarterly sales. Both companies reported financial results that surpassed analyst projections, reflecting positive momentum in their respective sectors. These developments highlight the current strength of Regeneron's pharmaceutical offerings and Hershey's sales capabilities during the most recent fiscal reporting period.